Biotech firm Absci secures $100M in financing from Eli Lilly and private equity investors, driving premarket gains.
Absci shares surged approximately 20% in premarket trading after announcing $100M in financing from Eli Lilly and several private equity firms. The company priced an underwritten offering of 13,495,277 shares at $7.41 per share.
The funding round includes participation from investors such as Adage and BVF. The move follows growing interest in biopharmaceutical innovation and strategic partnerships in the sector.
Premarket activity reflects investor optimism about the capital infusion and potential collaboration with Eli Lilly.